SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001072613-23-000627
Filing Date
2023-12-15
Accepted
2023-12-15 17:06:57
Documents
1
Group Members
ARCH VENTURE FUND VII, L.P.ARCH VENTURE FUND VIII OVERAGE, L.P.ARCH VENTURE FUND X OVERAGE, L.P.ARCH VENTURE FUND X, L.P.ARCH VENTURE PARTNERS VII, L.P.ARCH VENTURE PARTNERS VII, LLCARCH VENTURE PARTNERS VIII, LLCARCH VENTURE PARTNERS X OVERAGE, L.P.ARCH

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13D/A(#1) arch-sch13d_18782.htm SC 13D/A 655733
  Complete submission text file 0001072613-23-000627.txt   658052
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Subject) CIK: 0001885522 (see all company filings)

IRS No.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-94162 | Film No.: 231491247
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund XII, L.P. (Filed by) CIK: 0001906837 (see all company filings)

IRS No.: 873448430 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A